Linagliptina Pharmapath (Linagliptin)

Linagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, resulting in better control of blood sugar after meals and during fasting.

The prescribed dose of Linagliptina Pharmapath is determined by the treating physician based on the patient’s clinical condition, renal and hepatic function, and any concomitant medications. Patients should follow the exact dosing instructions provided by their healthcare professional.

Linagliptin is classified as pregnancy category C, meaning risk cannot be ruled out. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; the decision to continue therapy should be made by the prescriber after weighing benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin release without causing weight gain, unlike some sulfonylureas. Compared with SGLT2 inhibitors, it has a lower risk of genital infections but does not provide the same cardiovascular benefits observed with certain SGLT2 agents. Choice of therapy depends on individual patient factors and comorbidities.

Linagliptina Pharmapath should be stored at ambient temperature, preferably below 25 °C, in its original blister pack to protect from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed.

Serious adverse events reported with linagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Linagliptina Pharmapath is contraindicated in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is advised for individuals with a history of pancreatitis, severe hepatic impairment, or those taking medications that strongly inhibit P‑glycoprotein.